Drugs for pre-osteoporosis: Prevention or disease mongering?

BMJ

Volumn 336, Issue 7636, 2008, Pages 126-129

  Alonso Coello, Pablo ^a   García Franco, Alberto López ^b   Guyatt, Gordon ^c   Moynihan, Ray ^d  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Servicio Madrileño de Salud Red de Investigación en Servicios de Salud en Enfermedades Crónicas   (Spain)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE;

BONE DENSITY; DIARRHEA; DRUG INDUSTRY; FUNDING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY REACTION; JAW OSTEONECROSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; STROKE; VENOUS THROMBOEMBOLISM; WORLD HEALTH ORGANIZATION;

EID: 38949095210     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39435.656250.ad     Document Type: Review

References (25)

1. Moynihan R, Cassels A. Selling sickness: how drug companies are turning us all into patients. Sydney: Allen and Unwin, 2005.
2. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002;324:886-91.
3. International Osteoporosis Foundation. Key statistics for North America. www.iofbonehealth.org/facts-and-statistics.html.
4. Assessment of fracture riskand its application to screening for postmenopausal osteoporosis: report of a WHO study group. World Health Organ Tech Rep Ser 1994;843:1-129.
5. Cummings SR. A 55-year-old woman with osteopenia. JAMA 2006;296:2601-10.
6. Nelson HD, Morris CD, Kraemer DF, Mahon S, Carney N, Nygren PM, et al. Osteoporosis in postmenopausal women: diagnosis and monitoring. Evidence report/technology assessment 28. Rockville, MD: Agency for Healthcare Research and Quality, 2001.
7. Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005;142:734-41.
8. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
9. Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM. Effect of alendronate on vertebral fracture risk in women with bone mineral density T score of -1.6 to -2.5 at the femoral neck: the fracture intervention trial. Mayo Clin Proc 2005;80:343-9.
10. Kanis JA, Johnell O, Black DM, Downs RW, Sarkar S, Fuerst T, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of raloxifene evaluation trial. Bone 2003;33:293-300.
11. Siris ES, Simon JA, Barton IP, McClung MR, Grauer A. Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int 2007 Oct 30 Epub ahead of print.
12. Seeman E, Devogelaer J, Lorenc R, Spector T, Brixen K, Balogh A, et al. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 2007 Nov 12 Epub ahead of print.
13. Dirección General de Farmacia y Productos Sanitarios. Ficha de control de publicidad de medicamentos 2/2007. Madrid: Consejería de Sanidad Comunidad de Madrid, 2007.
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al, Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72.
15. j 15 Valensi P, Schwarz EH, Hall M, Felton AM, Maldonato A, Mathieu C. Pre-diabetes essential action: a European perspective. Diabetes Metab 2005;31:606-20.
16. Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 2002;21:1575-600.
17. Miller PD, Barlas S, Brenneman SK, Abbott TA, Chen YT, Barrett-Connor E, Siris ES. An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 2004;164:1113-20.
18. The relationship between bone density and incident vertebral fracture in men and women. J Bone Miner Res 2002;17:2214-21.
19. O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2006;(4):CD005326.
20. Stevenson M, Davis S, Lloyd-Jones M, Beverley C. The clinical effectiveness and cost-effectiveness of strontium ranelate forthe prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess 2007;11(4).
21. European Medicines Agency. EMEA recommends changes in the product in formation for Protelos/Osseor due to the risk of severe hypersensitivity reactions. Press release, 16 Nov 2007. www.emea.europa.eu/humandocs/PDFs/ EPAR/protelos/PressRelease_Protelos_41745807en.pdf.
22. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.
23. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37.
24. Department of Health and Human Services Public Health Service, Food and Drug Adminstration. ODS postmarketing safety review. August 2004. www.fda.gov/OHRMS/DOCKETS/ac/05/briefing/2005-4095B2_03_04-FDA-TAB3.pdf.
25. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007;18:1033-46.